AR072061A1 - Combinacion farmaceutica - Google Patents
Combinacion farmaceuticaInfo
- Publication number
- AR072061A1 AR072061A1 ARP090102041A ARP090102041A AR072061A1 AR 072061 A1 AR072061 A1 AR 072061A1 AR P090102041 A ARP090102041 A AR P090102041A AR P090102041 A ARP090102041 A AR P090102041A AR 072061 A1 AR072061 A1 AR 072061A1
- Authority
- AR
- Argentina
- Prior art keywords
- involved
- pharmaceutical combination
- diseases
- treatment
- radiotherapy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010016654 Fibrosis Diseases 0.000 abstract 3
- 230000004761 fibrosis Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000001959 radiotherapy Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [ 2,3-d] pyrimidin-5-yl Chemical group 0.000 abstract 1
- 206010051113 Arterial restenosis Diseases 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 206010025282 Lymphoedema Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 238000011278 co-treatment Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000002502 lymphedema Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- CPMDPSXJELVGJG-UHFFFAOYSA-N methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound OC=1NC2=CC(=CC=C2C=1C(=NC1=CC=C(C=C1)N(C(CN1CCN(CC1)C)=O)C)C1=CC=CC=C1)C(=O)OC CPMDPSXJELVGJG-UHFFFAOYSA-N 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000001210 retinal vessel Anatomy 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
Abstract
Una combinacion farmaceutica que puede ser util para el tratamiento de enfermedades en las que est implicada la proliferacion celular, en las que est implicada la migracion o apoptosis de celulas de mieloma, en las que est implicada la angiogenesis o en las que est implicada la fibrosis. La solicitante refiere a un metodo para el tratamiento de dichas enfermedades que comprende la administracion simult nea, separada o secuencial de cantidades eficaces de compuestos activos espec¡ficos y/o el cotratamiento con radioterapia, en una relacion que proporciona un efecto aditivo y sinergico, y al uso combinado de estos compuestos espec¡ficos y/o radioterapia para la fabricacion de preparaciones de combinacion farmaceuticas correspondientes. Reivindicacion 1: Combinacion farmaceutica caracterizada porque comprende el compuesto 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metilamino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona o una sal farmaceuticamente aceptable de la misma y el compuesto cido N-[4-[2-(2-amino-4,7-dihidro-4-oxo-1H-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil]-L-glut mico o una sal farmaceuticamente aceptable del mismo. Reivindicacion 21: El metodo de acuerdo con una cualquiera de las reivindicaciones 17 a 20, en el que la enfermedad se selecciona entre c nceres, diabetes, psoriasis, artritis reumatoide, sarcoma de Kaposi, hemangioma, nefropat¡as agudas y cronicas, ateroma, reestenosis arterial, enfermedades autoinmunes, inflamacion agua, asma, linfoedema, endometriosos, hemorragia uterina disfuncional, fibrosis cirrosis y enfermedades oft lmicas con proliferacion de vasos de la retina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157749 | 2008-06-06 | ||
| US7888208P | 2008-07-08 | 2008-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072061A1 true AR072061A1 (es) | 2010-08-04 |
Family
ID=40912046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102041A AR072061A1 (es) | 2008-06-06 | 2009-06-05 | Combinacion farmaceutica |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US20110178099A1 (es) |
| EP (2) | EP2293795B1 (es) |
| JP (2) | JP5993573B2 (es) |
| KR (1) | KR101760657B1 (es) |
| CN (1) | CN102056609B (es) |
| AR (1) | AR072061A1 (es) |
| AU (1) | AU2009254554B2 (es) |
| CA (1) | CA2726644C (es) |
| CO (1) | CO6280488A2 (es) |
| CY (2) | CY1116877T1 (es) |
| DK (2) | DK2293795T3 (es) |
| EA (1) | EA020046B1 (es) |
| EC (1) | ECSP10010716A (es) |
| ES (2) | ES2662824T3 (es) |
| HK (1) | HK1152640A1 (es) |
| HR (2) | HRP20151186T1 (es) |
| HU (2) | HUE025821T2 (es) |
| IL (1) | IL208953B (es) |
| LT (1) | LT2985025T (es) |
| MA (1) | MA32384B1 (es) |
| ME (1) | ME02273B (es) |
| MX (1) | MX338047B (es) |
| MY (1) | MY158929A (es) |
| NZ (1) | NZ588957A (es) |
| PE (1) | PE20100084A1 (es) |
| PL (2) | PL2985025T3 (es) |
| PT (2) | PT2985025T (es) |
| RS (2) | RS57035B1 (es) |
| SI (2) | SI2293795T1 (es) |
| TW (1) | TWI447113B (es) |
| UA (1) | UA102258C2 (es) |
| UY (1) | UY31866A (es) |
| WO (1) | WO2009147218A1 (es) |
| ZA (1) | ZA201007594B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| EA029996B1 (ru) * | 2008-06-06 | 2018-06-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона |
| US20140350022A1 (en) * | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| AU2014296032A1 (en) | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| EP3365180B1 (en) * | 2015-10-21 | 2019-12-18 | Capsugel Belgium NV | Printing process for oral dosage forms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96531A (en) * | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
| WO2001014379A2 (en) * | 1999-08-23 | 2001-03-01 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| US20040204458A1 (en) * | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
| US7148249B2 (en) * | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| CA2595573A1 (en) * | 2004-01-23 | 2005-08-04 | D. James Koropatnick | Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060041013A1 (en) * | 2004-08-18 | 2006-02-23 | Brittain Jason E | Alanosine formulations and methods of use |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| WO2008021410A2 (en) * | 2006-08-14 | 2008-02-21 | Sicor Inc. | Highly pure pemetrexed diacid and processes for the preparation thereof |
-
2009
- 2009-06-04 JP JP2011512132A patent/JP5993573B2/ja not_active Expired - Fee Related
- 2009-06-04 CN CN2009801211276A patent/CN102056609B/zh not_active Expired - Fee Related
- 2009-06-04 PE PE2009000779A patent/PE20100084A1/es not_active Application Discontinuation
- 2009-06-04 HU HUE09757599A patent/HUE025821T2/en unknown
- 2009-06-04 ME MEP-2015-165A patent/ME02273B/me unknown
- 2009-06-04 WO PCT/EP2009/056891 patent/WO2009147218A1/en active Application Filing
- 2009-06-04 PL PL15179438T patent/PL2985025T3/pl unknown
- 2009-06-04 KR KR1020107027337A patent/KR101760657B1/ko active IP Right Grant
- 2009-06-04 RS RS20180319A patent/RS57035B1/sr unknown
- 2009-06-04 EP EP09757599.7A patent/EP2293795B1/en active Active
- 2009-06-04 AU AU2009254554A patent/AU2009254554B2/en not_active Ceased
- 2009-06-04 EP EP15179438.5A patent/EP2985025B1/en active Active
- 2009-06-04 CA CA2726644A patent/CA2726644C/en not_active Expired - Fee Related
- 2009-06-04 UA UAA201100102A patent/UA102258C2/ru unknown
- 2009-06-04 LT LTEP15179438.5T patent/LT2985025T/lt unknown
- 2009-06-04 EA EA201001853A patent/EA020046B1/ru not_active IP Right Cessation
- 2009-06-04 SI SI200931315T patent/SI2293795T1/sl unknown
- 2009-06-04 PL PL09757599T patent/PL2293795T3/pl unknown
- 2009-06-04 ES ES15179438.5T patent/ES2662824T3/es active Active
- 2009-06-04 US US12/995,882 patent/US20110178099A1/en not_active Abandoned
- 2009-06-04 MX MX2010012937A patent/MX338047B/es active IP Right Grant
- 2009-06-04 DK DK09757599.7T patent/DK2293795T3/en active
- 2009-06-04 ES ES09757599.7T patent/ES2552238T3/es active Active
- 2009-06-04 SI SI200931819T patent/SI2985025T1/en unknown
- 2009-06-04 NZ NZ588957A patent/NZ588957A/xx not_active IP Right Cessation
- 2009-06-04 MY MYPI2010005701A patent/MY158929A/en unknown
- 2009-06-04 DK DK15179438.5T patent/DK2985025T3/en active
- 2009-06-04 RS RS20150690A patent/RS54293B1/en unknown
- 2009-06-04 HU HUE15179438A patent/HUE037291T2/hu unknown
- 2009-06-04 PT PT151794385T patent/PT2985025T/pt unknown
- 2009-06-04 UY UY0001031866A patent/UY31866A/es not_active Application Discontinuation
- 2009-06-04 PT PT97575997T patent/PT2293795E/pt unknown
- 2009-06-05 AR ARP090102041A patent/AR072061A1/es unknown
- 2009-06-05 TW TW098118817A patent/TWI447113B/zh not_active IP Right Cessation
-
2010
- 2010-10-25 ZA ZA2010/07594A patent/ZA201007594B/en unknown
- 2010-10-26 IL IL208953A patent/IL208953B/en active IP Right Grant
- 2010-12-03 CO CO10152525A patent/CO6280488A2/es not_active Application Discontinuation
- 2010-12-06 MA MA33401A patent/MA32384B1/fr unknown
- 2010-12-23 EC EC2010010716A patent/ECSP10010716A/es unknown
-
2011
- 2011-06-24 HK HK11106535.6A patent/HK1152640A1/xx not_active IP Right Cessation
-
2013
- 2013-04-24 US US13/869,139 patent/US20130237549A1/en not_active Abandoned
-
2014
- 2014-10-16 JP JP2014211603A patent/JP2015007143A/ja not_active Withdrawn
-
2015
- 2015-03-05 US US14/639,265 patent/US20150174126A1/en not_active Abandoned
- 2015-11-03 CY CY20151100977T patent/CY1116877T1/el unknown
- 2015-11-05 HR HRP20151186TT patent/HRP20151186T1/hr unknown
-
2016
- 2016-05-06 US US15/147,929 patent/US20160250218A1/en not_active Abandoned
-
2018
- 2018-04-16 HR HRP20180602TT patent/HRP20180602T1/hr unknown
- 2018-04-17 CY CY20181100403T patent/CY1120505T1/el unknown
- 2018-05-01 US US15/967,607 patent/US20180243308A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072061A1 (es) | Combinacion farmaceutica | |
| JP7030656B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物 | |
| Cavalli et al. | Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies | |
| EA200700886A1 (ru) | Соединение тиадиазола и его применение | |
| CU20220028A7 (es) | Compuestos derivados sustituidos del anillo de imidazol fusionado | |
| AR118108A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| CN103635188B (zh) | 使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物 | |
| AR044114A1 (es) | Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma o angiogenesis | |
| US11389512B2 (en) | Use of low molecular weight fractions of human serum albumin in treating diseases | |
| SG157242A1 (en) | Medicaments with hm74a receptor agonist activity | |
| AR097388A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| CN101801362A (zh) | 用于治疗病症的方法和组合物 | |
| BRPI0821683B8 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
| EP2642999A1 (en) | Methods of treatment using selective bcl-2 inhibitors | |
| EA200970835A1 (ru) | Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета | |
| CL2013001712A1 (es) | Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras. | |
| CR20210271A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| JP2006514611A (ja) | 免疫疾患の治療のためのＬｃｋインヒビターの使用 | |
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| JP2007520564A5 (es) | ||
| NO20085375L (no) | Nitrerte hetrosykliske forbindelser som endotelin-reseptorantagonist | |
| RU2014115733A (ru) | Новая соль и медицинское применение | |
| Wei et al. | Extracellular matrix in synovium development, homeostasis and arthritis disease | |
| JP2007518768A (ja) | 有機化合物の組み合わせ物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |